Cullinan Oncology, Inc. (CGEM)
NASDAQ: CGEM · IEX Real-Time Price · USD
23.17
-0.64 (-2.69%)
At close: May 17, 2024, 4:00 PM
23.47
+0.30 (1.29%)
After-hours: May 17, 2024, 7:59 PM EDT
Cullinan Oncology Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Cullinan Oncology stock have an average target of 32, with a low estimate of 26 and a high estimate of 40. The average target predicts an increase of 38.11% from the current stock price of 23.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CGEM stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 3 | 4 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $29 → $28 | Strong Buy | Maintains | $29 → $28 | +20.85% | May 16, 2024 |
| Wedbush | Wedbush | Buy Reiterates $36 | Buy | Reiterates | $36 | +55.37% | May 16, 2024 |
| Stifel | Stifel | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +72.64% | May 1, 2024 |
| JonesTrading | JonesTrading | Strong Buy Maintains $22 → $26 | Strong Buy | Maintains | $22 → $26 | +12.21% | Apr 17, 2024 |
| BTIG | BTIG | Strong Buy Maintains $20 → $30 | Strong Buy | Maintains | $20 → $30 | +29.48% | Apr 17, 2024 |
Financial Forecast
Revenue This Year
1.58M
Revenue Next Year
15.23M
from 1.58M
Increased by 864.72%
EPS This Year
-3.81
from -3.69
EPS Next Year
-3.41
from -3.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.4M | 50.1M | 64.5M | 58.6M | 421.1M |
| Avg | 1.6M | 15.2M | 34.6M | 14.2M | 118.6M |
| Low | n/a | n/a | n/a | n/a | 3.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 3,072.3% | 323.2% | 69.6% | 2,868.3% |
| Avg | - | 864.7% | 127.0% | -59.0% | 735.9% |
| Low | - | - | - | - | -72.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.37 | -2.85 | -2.53 | -2.76 | 0.09 |
| Avg | -3.81 | -3.41 | -3.34 | -3.26 | -2.16 |
| Low | -4.36 | -3.87 | -4.10 | -4.35 | -4.17 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.